"As a result of improvements identified during the strategic review, the Company anticipates that the current cash balance of $8.8M, in association with the forecast R&D tax rebates, will provide the Company with operating capital for FY17 and enable multiple cost saving initiatives, launch of new products into the market which have not been forecast into the current revenue as well as maintain sales growth."
The New Admedus, page-47
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.19 |
Change
-0.010(0.08%) |
Mkt cap ! $257.6M | |||
| Open | High | Low | Value | Volume |
| $12.19 | $12.20 | $11.60 | $173.1K | 14.51K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9 | $11.97 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.19 | 28 | 1 |
View Market Depth
| Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |